Retrospective analysis of kidney's safety of edaravone injection
10.3760/cma.j.issn.1008-5734.2015.06.003
- VernacularTitle:依达拉奉注射液肾脏安全性的回顾性研究
- Author:
Yang ZHANG
1
;
Limin SHI
1
;
Sheng CHENG
1
;
Xiao LUO
1
;
Aiping WEN
1
;
Yin LIAO
1
Author Information
1. 100050,首都医科大学附属北京友谊医院药剂科
- Publication Type:Journal Article
- Keywords:
Renal insufficiency;
Creatinine;
Retrospective studies;
Edaravone
- From:
Adverse Drug Reactions Journal
2015;(6):408-411
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the kidney's safety of edaravone injection. Methods The clinical data of patients who were hospitalized in Neurology Department of Beijing Friendship Hospital, Capital Medical University from January 2014 to June 2014 and had complete medical records,aged ≥45 years and received edaravone injection for cerebrovascular disease were collected and analyzed retrospectively. The patients' information,complications,time of application of edaravone injection(30 mg, twice daily,IV infusion),drug combination and the levels of serum creatinine were recorded. The serum creatinine elevated to ≥26. 4 μmol/ L,or increased 1. 5 times of baseline were the diagnostic criteria of kidney injury after receiving edaravone injection. Results A total of 237 patients' medical records comprised 163 male and 74 female,with average age of(65 ± 9)years(50 to 86 years)were collected. The average time of edaravone injection administration was 11 days(2 to 26 days)for all patients. Eleven patients(4. 6% )developed kidney injury. There was no statistical significance in the incidence of kidney injury between male and female patients[4. 9%(8 / 163)vs. 4. 1%(3 / 74),P > 0. 05 for all comparisons]. The incidence of kidney injury in patients who were 75 years or older was higher than those in the patients who aged between 45 to 59 years and 60 to 74 years[11. 4%(4 / 35)vs. 3. 8%(3 / 80),3. 3%(4 / 122), P < 0. 05 for all comparisons]. The incidence of kidney injury in patients with chronic renal insufficiency or renal cyst was higher than that in patients without chronic renal insufficiency or renal cyst[9. 1%(2 / 22) vs. 4. 2%(9 / 215),7. 7%(2 / 26)vs. 4. 3%(9 / 211),P < 0. 05]. The average level of serum creatinine in the 11 patients before treatment was(68 ± 24)μmol/ L(26 to 113 μmol/ L)and increased to(101 ± 36)μmol/ L(52 to 187 μmol/ L)after receiving edaravone injection for 9 to 13 days(average days of 11). The serum creatinine levels of the 11 patients returned to the levels before administration after edaravone withdrawal. The 11 patients with kidney injury were all co-treated with three or more kinds of drugs. Conclusions The kidney's safety of edaravone injection is higher in patients who were under 75 years, without chronic renal insufficiency and renal cyst. Dynamic monitoring of kidney function should be given in patients who are 75 years or older,with chronic renal insufficiency or renal cyst when receiving edaravone injection.
